Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS) reports a proposed sale of 33,600 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $1,931,664. The filing lists approximately 159,391,229 shares outstanding and indicates an approximate sale date of 09/02/2025 on NASD. The securities being sold were primarily acquired as compensation (restricted stock units) and via option exercises on various dates between 2015 and 2020, with individual lots and quantities detailed in the filing. No securities sold in the past three months are reported.
Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS) reports a proposed sale of 11,130 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $552,865.00. The filing lists 159,391,229 shares outstanding and an approximate sale date of 09/02/2025 on Nasdaq. The securities were acquired as Restricted Stock Units on 01/15/2021 (listed amount acquired: 23,976) and a payment date of 01/15/2017 with Cash noted under payment. No securities were reported sold in the past three months, and the filer attests they are unaware of undisclosed material adverse information.
Ionis Pharmaceuticals insider sale notice: This Form 144 shows a proposed sale of 10,000 shares of Ionis common stock through Stifel Nicolaus & Company, with an aggregate market value of $503,671. The filing reports the shares were acquired as restricted stock units on 01/15/2019 (16,802 units originally) and payment was in cash. The filer previously sold 10,000 shares on 08/05/2025 for $428,593. The company has 159,391,229 shares outstanding, so the proposed sale represents approximately 0.0063% of outstanding shares. The filer attests there is no undisclosed material information.
Ionis Pharmaceuticals, Inc. notified the market of a proposed sale of 13,050 shares of its common stock through Stifel Nicolaus & Company Inc., with an approximate aggregate market value of $711,418.00. The filing states the shares represent part of outstanding common stock of 159,391,229 shares and lists an approximate sale date of 09/02/2025 on Nasdaq. The filer acquired these shares on 01/04/2021 by exercising options from the issuer and plans to receive cash as payment. The notice reports no securities sold in the past three months for the account and includes the required representation that the seller is not aware of any undisclosed material adverse information.
Form 144 notice for Ionis Pharmaceuticals (IONS) reports a proposed sale of 20,000 shares of common stock through Stifel Nicolaus & Company on 09/02/2025 on Nasdaq with an aggregate market value of $1,018,296. The filing states there are 159,391,229 shares outstanding.
The securities to be sold were acquired as restricted stock units on 01/15/2017 totaling 78,321 shares, with payment noted as cash. The filing also discloses a prior sale by Lynne Parshall of 5,000 shares on 08/06/2025 for gross proceeds of $209,646. The notice includes the standard representation that the seller has no undisclosed material information.
Ionis Pharmaceuticals reported positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG). Across nearly 1,100 patients required to remain on standard-of-care lipid-lowering therapy, olezarsen produced highly statistically significant, placebo-adjusted mean reductions in fasting triglycerides of up to 72% and a highly statistically significant 85% reduction in acute pancreatitis events. Both 80 mg and 50 mg monthly doses met the primary endpoint at six months with strong p-values (p<0.0001), and the company described safety and tolerability as favorable.
Ionis Pharmaceuticals Form 144 notice: A holder intends to sell 1,427 shares of Ionis common stock through Insight Securities on the NYSE. The shares were acquired as compensation from Ionis on 08/22/2025 and the planned sale date is listed as 08/22/2025. The filing reports no shares sold in the past three months by the seller. The filing states the seller represents they have no undisclosed material adverse information about the issuer.
Allene M. Diaz, a director of Ionis Pharmaceuticals (IONS), reported the sale of 1,427 shares of common stock on 08/22/2025 at a weighted-average price of $42.5278 per share, reducing her direct holdings to 18,368 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted May 3, 2023, and the filing notes the shares were sold in multiple transactions at prices ranging $42.30 to $42.75. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Ionis Pharmaceuticals announced that the FDA has approved DAWNZERA (donidalorsen) to prevent hereditary angioedema (HAE) attacks in adults and children 12 and older. DAWNZERA is described as the first and only RNA-targeted medicine approved for HAE, given as an 80 mg self-administered subcutaneous autoinjector every four or eight weeks.
The approval is based on the Phase 3 OASIS-HAE study, where DAWNZERA given every four weeks reduced monthly HAE attack rates by 81% versus placebo over 24 weeks, and by 87% from the second dose. It also cut moderate-to-severe attacks by about 90%. In the OASISplus extension, DAWNZERA showed a 94% mean attack rate reduction from baseline across dosing groups after one year.
In patients switching from other prophylactic treatments, DAWNZERA lowered mean attack rates by 62% over 16 weeks, and 84% of surveyed patients preferred it, citing better disease control and easier administration. The most common side effects were injection site reactions, upper and urinary tract infections, and abdominal discomfort.
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported option exercise and share sale transactions on 08/18/2025. He was granted or exercised a non-qualified stock option with a $32.60 exercise price covering 10,000 shares exercisable from 01/03/2023 and expiring 01/02/2032, which increased his direct common stock holdings to 103,466 shares. On the same date, he sold 10,000 shares pursuant to a Rule 10b5-1 trading plan adopted May 13, 2025, for a weighted average price of $43.9776 per share (sales occurred at prices between $43.75 and $44.25). Following the sale, his reported direct common stock ownership was 93,466 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on behalf of Mr. Bennett.